Table 5 Estimation of the hazard ratio for disease-specific survival
From: Lymph node density as a prognostic variable in node-positive bladder cancer: a meta-analysis
Study | HR estimation | Co-factors | Analysis results |
|---|---|---|---|
Herr [5] | P value, event no. | pT stage, pN stage, no. of LNs removed, no. of positive LNs | Significant |
Wiesner [20] | HR, 95Â % CI | No. of LNs removed, no. of positive LNs | Significant |
Furukawa [21] | HR, 95Â % CI | No. of positive LNs, laterality of positive LNs, adjuvant chemotherapy | Significant |
Guzzo [22] | HR, 95Â % CI | Age, sex, diversion type, pT stage, adjuvant chemotherapy | Not significant |
May [24] | HR, 95Â % CI | Age, sex, radical cystectomy time frame, pT stage, pN stage, tumor grade, concomitant carcinoma in situ, adjuvant chemotherapy, no. of LNs removed | Significant |
Jensen [25] | HR, 95Â % CI | Age, sex, pT stage, pN stage, metastasis above the aortic bifurcation, extracapsular extension, volume dependent LN density, diameter of largest LN, volume of metastatic LNs | Not significant |
Morgan [26] | HR, 95Â % CI | Age, Charlson comorbidity index, pT stage, tumor grade, no. of LNs removed, adjuvant chemotherapy, diversion type, year of surgery, surgeon volume, transfusion | Significant |
Kassouf [27] | HR, 95Â % CI | Age, sex, tumor grade, pT stage, margin status, lymphovascular invasion, adjuvant chemotherapy, concomitant carcinoma in situ | Significant |
Masson-Lecomte [28] | P value, event no. | pT stage, extracapsular extension, adjuvant chemoethrapy | Not significant |
Kwon [30] | HR, 95Â % CI | pT stage, pN stage, no. of positive LNs, adjuvant chemotherapy | Not significant |